Merit Medical Systems, Inc. reported a notable increase in financial performance for the second quarter of 2026, with net sales reaching $418.8 million, a 10% increase from $382.5 million in the same period of 2025. For the first half of 2026, the company generated $800.7 million in sales, up 9% from $737.8 million year-over-year. The gross profit margin also improved, rising to 51.4% for the second quarter and 50.0% for the first half, compared to 48.2% and 48.3%, respectively, in the prior year. Net income for the second quarter was $38.8 million, or $0.65 per share, compared to $32.6 million, or $0.54 per share, in the previous year. For the first half, net income was $79.8 million, or $1.33 per share, up from $62.7 million, or $1.03 per share.
The company experienced significant growth in both domestic and international markets, with domestic sales increasing by 11% to $252.1 million in the second quarter, while international sales rose by 7.3% to $166.8 million. The increase in sales was attributed to strong demand across various product categories, particularly in foundational and therapeutic products. Notably, the company completed the acquisition of View Point Medical, Inc. on April 1, 2026, which is expected to enhance its product offerings in the diagnostic and localization space.
Merit Medical's operational metrics reflected positive trends, with cash, cash equivalents, and restricted cash totaling $450.9 million as of June 30, 2026. The company also reported a net available borrowing capacity of approximately $697 million under its Amended Fourth A&R Credit Agreement. The workforce expanded, contributing to increased selling, general, and administrative expenses, which rose by 14.3% in the second quarter compared to the previous year. This increase was primarily driven by higher labor costs, including commissions and stock-based compensation.
The filing also highlighted the impact of recent acquisitions on the company's financials. The View Point acquisition, which included the OneMark Detection Imaging System, is expected to contribute to future revenue growth. Additionally, the company reported a pre-tax gain of $12.5 million from the sale of its DualCap product line to Health Line International Corporation, which closed in February 2026. The company anticipates continued growth driven by its strategic initiatives and product innovations.
Looking ahead, Merit Medical remains optimistic about its growth trajectory, supported by a strong cash position and ongoing investments in product development and acquisitions. The company is focused on integrating its recent acquisitions and leveraging its expanded product portfolio to capture market share in the medical device industry.
About MERIT MEDICAL SYSTEMS INC
Merit Medical Systems, Inc. designs, manufactures, and markets proprietary medical devices for interventional, diagnostic, and therapeutic procedures across cardiology, radiology, oncology, critical care, and endoscopy. Its products include catheters, stents, biopsy systems, and procedural kits, serving hospitals and healthcare providers worldwide. The company emphasizes innovation, quality, and customer focus, operating through two segments—cardiovascular and endoscopy—and leveraging global R&D, manufacturing, and distribution to address unmet healthcare needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov